A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
← catalyst calendarNCT07503808 · readout in 345 d
Sponsored by IDEAYA Biosciences (industry) · IDYA — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
150estimated
Sites
15
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-24 | actual | When the study began enrolling |
| Primary completion | 2027-07-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-07-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Esophageal Squamous Cell Carcinoma
- High Grade Serous Ovarian Cancer
- Head and Neck Squamous Cell Carcinoma
- Colorectal Cancer
- Castration-resistant Prostate Cancer
- Non Small Cell Lung Cancer
- Endometrium Cancer
- Triple Negative Breast Cancer
Intervention
- Drug: IDE034
Primary outcomes
what the primary-completion date above is the date OFSafety and tolerability of IDE034 in Part 1 dose escalation
measured 21 days following the first dose of IDE034
Safety and tolerability of IDE034 in Part 2 dose expansion
measured Approximately 20 months total study duration
To evaluate preliminary anti-tumor activity of IDE034 in Part 2 dose expansion
measured Time Frame: Approximately 20 months total study duration
To evaluate preliminary anti-tumor activity of IDE034 in Part 2 dose expansion
measured Time Frame: Approximately 20 months total study duration
Permalink · IDYA's whole pipeline · Catalyst calendar · Every registered study · What changed